These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33052246)

  • 1. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma.
    Chan TC; Wu WJ; Li WM; Shiao MS; Shiue YL; Li CF
    Theranostics; 2020; 10(25):11775-11793. PubMed ID: 33052246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment.
    Hsieh HY; Jou YC; Tung CL; Tsai YS; Wang YH; Chi CL; Lin RI; Hung SK; Chuang YM; Wu SF; Li C; Shen CH; Chan MWY; Hsu CD
    Oncogene; 2018 Feb; 37(5):673-686. PubMed ID: 29035390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder.
    Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF
    J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder.
    Lee YE; Chan TC; Tian YF; Liang PI; Shiue YL; Chen YS; He HL
    Urol Oncol; 2019 May; 37(5):299.e7-299.e18. PubMed ID: 30660494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tract.
    Lee HY; Yeh BW; Chan TC; Yang KF; Li WM; Huang CN; Ke HL; Li CC; Yeh HC; Liang PI; Shiue YL; Wu WJ; Li CF
    Oncotarget; 2017 Jul; 8(29):47216-47229. PubMed ID: 28525382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EMP2 induces cytostasis and apoptosis via the TGFβ/SMAD/SP1 axis and recruitment of P2RX7 in urinary bladder urothelial carcinoma.
    Li CF; Chan TC; Pan CT; Vejvisithsakul PP; Lai JC; Chen SY; Hsu YW; Shiao MS; Shiue YL
    Cell Oncol (Dordr); 2021 Oct; 44(5):1133-1150. PubMed ID: 34339014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPX2 underexpression indicates poor prognosis in patients with urothelial carcinomas of the upper urinary tract and urinary bladder.
    Chang IW; Lin VC; Hung CH; Wang HP; Lin YY; Wu WJ; Huang CN; Li CC; Li WM; Wu JY; Li CF
    World J Urol; 2015 Nov; 33(11):1777-89. PubMed ID: 25813210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MCM10 overexpression implicates adverse prognosis in urothelial carcinoma.
    Li WM; Huang CN; Ke HL; Li CC; Wei YC; Yeh HC; Chang LL; Huang CH; Liang PI; Yeh BW; Chan TC; Li CF; Wu WJ
    Oncotarget; 2016 Nov; 7(47):77777-77792. PubMed ID: 27780919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulator of cullins-1 expression knockdown suppresses the malignant progression of muscle-invasive transitional cell carcinoma by regulating mTOR/DEPTOR pathway.
    Wang W; Chen H; Liu Z; Qu P; Lan J; Chen H; Zou L; Qiu J
    Br J Cancer; 2016 Feb; 114(3):305-13. PubMed ID: 26742010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of replication protein A3 is associated with unfavorable outcome in bladder urothelial carcinoma.
    Sun D; Zhang K; Fu Q; Zhang H; Liu S; Wang H; Xu Z; Wang J
    J Cancer Res Ther; 2021 Jul; 17(3):771-776. PubMed ID: 34269312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SLC14A1 (UT-B) gene rearrangement in urothelial carcinoma of the bladder: a case report.
    Guo Z; Niu X; Fu G; Yang B; Chen G; Sun S
    Diagn Pathol; 2020 Jul; 15(1):94. PubMed ID: 32703295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The autocrine glycosylated-GREM1 interacts with TGFB1 to suppress TGFβ/BMP/SMAD-mediated EMT partially by inhibiting MYL9 transactivation in urinary carcinoma.
    Chan TC; Pan CT; Hsieh HY; Vejvisithsakul PP; Wei RJ; Yeh BW; Wu WJ; Chen LR; Shiao MS; Li CF; Shiue YL
    Cell Oncol (Dordr); 2023 Aug; 46(4):933-951. PubMed ID: 36920729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma.
    Liang PI; Lai HY; Chan TC; Li WM; Hsing CH; Huang SK; Hsieh KL; Tseng WH; Chen TJ; Li WS; Chen HD; Kuo YH; Li CF
    BMC Cancer; 2023 Jun; 23(1):599. PubMed ID: 37380971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
    Minato A; Noguchi H; Tomisaki I; Fukuda A; Kubo T; Nakayama T; Fujimoto N
    Cancer Control; 2018; 25(1):1073274818800269. PubMed ID: 30213195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylomics analysis identifies ZNF671 as an epigenetically repressed novel tumor suppressor and a potential non-invasive biomarker for the detection of urothelial carcinoma.
    Yeh CM; Chen PC; Hsieh HY; Jou YC; Lin CT; Tsai MH; Huang WY; Wang YT; Lin RI; Chen SS; Tung CL; Wu SF; Chang DC; Shen CH; Hsu CD; Chan MW
    Oncotarget; 2015 Oct; 6(30):29555-72. PubMed ID: 26320192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma.
    Wu WR; Lin JT; Pan CT; Chan TC; Liu CL; Wu WJ; Sheu JJ; Yeh BW; Huang SK; Jhung JY; Hsiao MS; Li CF; Shiue YL
    Theranostics; 2020; 10(2):707-724. PubMed ID: 31903146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A genetically defined disease model reveals that urothelial cells can initiate divergent bladder cancer phenotypes.
    Wang L; Smith BA; Balanis NG; Tsai BL; Nguyen K; Cheng MW; Obusan MB; Esedebe FN; Patel SJ; Zhang H; Clark PM; Sisk AE; Said JW; Huang J; Graeber TG; Witte ON; Chin AI; Park JW
    Proc Natl Acad Sci U S A; 2020 Jan; 117(1):563-572. PubMed ID: 31871155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of CRTAC1 in Urothelial Carcinoma Promotes Tumor Aggressiveness and Confers Poor Prognosis.
    Li WM; Chan TC; Wei YC; Li CF; Ke HL; Wu WJ; Hsu CC; Wang SC; Yeh CF
    Front Biosci (Landmark Ed); 2023 Sep; 28(9):217. PubMed ID: 37796703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ERCC1 as a Prognostic and Predictive Biomarker for Urothelial Carcinoma of the Bladder following Radical Cystectomy.
    Klatte T; Seitz C; Rink M; Rouprêt M; Xylinas E; Karakiewicz P; Susani M; Shariat SF
    J Urol; 2015 Nov; 194(5):1456-62. PubMed ID: 26162296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.